Also, given how potentially lucrative breast cancer treatment...

Also, given how potentially lucrative breast cancer treatment is. If Efti was a flyer in this indication it would have no problems attracting significant interest within the industry.
So far, the company has given zero indication that there is any third party interest in Efti for the treatment of MBC.
That doesn’t mean there isn’t. But at this point the company has not given even the tiniest hint. The FDA and EMA have given support but there’s no fast track or anything else. We proceed as if we are going it alone. Some sort of external interest in Efti for MBC treatment with significant dollars attached would would do the companies prospects a world of good.